Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Dormant

Current status date:

2018-08-02

Original market date: See footnote 1

2012-02-21

Product name:

SUMMIT ULTRA

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02360357

Product Monograph/Veterinary Labelling:

Date: 2019-08-22 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PENDOPHARM DIVISION OF PHARMASCIENCE INC
100 6111 Royalmount Ave
Montreal
Quebec
Canada H4P 2T4

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

2

Schedule(s):

OTC

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.04.92  ,  12:20.04 

Anatomical Therapeutic Chemical (ATC): See footnote 4

M03BA53 METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Active ingredient group (AIG) number:See footnote5

0248961002

List of active ingredient(s)
Active ingredient(s) Strength
IBUPROFEN 400 MG
METHOCARBAMOL 500 MG
Version 4.0.2
Date modified: